
Join to View Full Profile
900 W Faris Rd2ND floorGreenville, SC 29605
Phone+1 864-455-8898
Fax+1 864-455-5164
Are you Dr. Crosswell?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Howland Crosswell, MD is a pediatric hematologist/oncologist in Greenville, South Carolina. He is currently licensed to practice medicine in South Carolina, West Virginia, and North Carolina.
Education & Training
- Emory University School of MedicineFellowship, Pediatric Hematology/Oncology, 2006
- University of Louisville School of MedicineResidency, Pediatrics, 1997 - 2000
- Medical University of South CarolinaClass of 1997
- University of South Carolina School of MedicineClass of 1997
Certifications & Licensure
- NC State Medical License 2014 - 2025
- SC State Medical License 2000 - 2025
- WV State Medical License 2015 - 2016
- GA State Medical License 2003 - 2007
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- Financial distress and medical financial hardship among young adult survivors of blood cancer.Susan K Parsons, Rachel Murphy-Banks, Angie Mae Rodday, Michael E Roth, Kimberly Miller
JNCI Cancer Spectrum. 2024-09-02 - 2 citationsBrentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage
Haematologica. 2024-03-01 - 1 citationsComparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics.Elizabeth J Siembida, Holli A Loomans-Kropp, Irene Tami-Maury, David R Freyer, Lillian Sung
The Oncologist. 2022-05-06
Press Mentions
- Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRISDecember 2nd, 2018